R&D News | pharmaphorum

News

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.

News

The puzzle of Alzheimer's, HCP hand holds digital graphic of brain and missing puzzle piece

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.

News

Final judgement favours TwinStrand in Guardant patent case

Court issues final judgement in favour of TwinStrand and the University of Washington in their patent infringement suit against Guardant Health.

News

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care.

News

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Roche’s Genentech has agreed a deal worth up to $2.3 billion to develop and sell Hanmi Pharmaceutical’s experimental obesity drug HM17321.

News

Positive Ph1 results for AC Immune's NLRP3 inflammasome inhi...

AC Immune has announced positive interim results from its Ph 1 study of ACI-19764 – a NLRP3 inflammasome inhibitor targeting chronic inflammation.

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

Final judgement favours TwinStrand in Guardant patent case

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Roche’s Genentech strikes $2.3bn deal for Hanmi obesity drug...

Positive Ph1 results for AC Immune's NLRP3 inflammasome inhi...

ESMO26: Tango sees 82% ORR with combo in pancreatic cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks